Current Report Filing (8-k)
June 25 2019 - 7:59AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 21, 2019
|
MERIDIAN BIOSCIENCE, INC.
|
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Ohio
|
|
0-14902
|
|
31-0888197
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
3471 River Hills Drive
Cincinnati,
Ohio
|
|
45244
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code
(513)
271-3700
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, no par value
|
|
VIVO
|
|
NASDAQ
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (17 CFR §230.405) or Rule
12b-2
of the Securities Exchange Act of 1934 (17CFR
§240.12b-2).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On June 21, 2019, Meridian Bioscience, Inc.
(
Meridian
or the
Company
) and Eric S. Rasmussen entered into a Separation Agreement and General Release (the
Separation Agreement
) which provides that Mr. Rasmussens last day of
employment as Meridians Executive Vice President and Chief Financial Officer shall be June 28, 2019. Mr. Rasmussen is resigning from his positions with Meridian to pursue other opportunities. Under the Separation Agreement the
Company has agreed to reimburse Mr. Rasmussen for certain expenses and make severance payments consisting of: (i) $450,000 which equates to one year of base salary; (ii) $75,000 in lieu of corporate bonus opportunity for the 2019 fiscal year;
and (iii) $225,000 relating to restricted stock units that would have otherwise been forfeited pursuant to their terms.
Effective
June 28, 2019 Meridian appointed Bryan T. Baldasare, currently its Senior Vice President, Corporate Controller, Treasurer and Chief Accounting Officer, to serve as Interim Chief Financial Officer (Interim Principal Financial Officer). The
information required by Form
8-K
Item 5.02 (c)(2) and (3) regarding Mr. Baldasare is incorporated herein by reference from the Companys
Form 8-K
filed on December 12, 2018.
The description above of the Separation Agreement is qualified in its entirety by the copy of the
Separation Agreement filed as Exhibit 10.1 with this report and is incorporated by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
MERIDIAN BIOSCIENCE, INC.
|
|
|
|
|
Date: June 25, 2019
|
|
|
|
|
|
By: /s/ Jack Kenny
|
|
|
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
|
|
(Principal Executive Officer)
|
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Sep 2023 to Sep 2024